The 5 constituents in the munKNEE Psychedelic Drug Stocks Index continue to exhibit extreme volatility declining almost 8%, on average, this week after a 22% jump the previous week and a 6.5% decline the week before that. Last week's increase was based on a number of favorable Q3 financial reports but this week's decline is based on no news of note. Here's how they rank, in ascending order, according to their performances this week, last week and YTD.

1. Mind Medicine (MNMD): down 19.1% this week; up 25.1% the previous week; up 21.5% YTD
   • is primarily focused on the use of LSD and MNMA. Go here for much more extensive information on LSD and  here for much more extensive information on MNMA.
2. Compass Pathways (CMPS): down 17.8% this week; up 21.1% the previous week; down 32.5% YTD
   • is focused on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
3. Atai Life Sciences (ATAI): down 11.4% this week; up 24.5% the previous week; down 54.7% YTD
   • is focused on the use of ketamine, DMT and ibogaine.  Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
4. Incannex Healthcare (IXHL): up 1.2% this week; up 10.0% the previous week; down 60.0% YTD
   • is researching and developing therapies and products with the world's largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
5. GH Research (GHRS): up 3.3% this week; up 22.9% the previous week; down 8.1% YTD
   • is primarily focused on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine.
   • Read: GH Research Reports Third Quarter Financial Results and Provides Business Updates

Summary

The munKNEE Psychedelic Drug Stocks Index was down 7.7% this week, up 22.0% the previous week and down 6.5% the week before that, and is now down 24.4% YTD.

More By This Author:

If EDA Software Is The Next Big Thing, Who Is Best Positioned To Capitalize?
Canopy Growth Q2 Financials Show Improvement
Curaleaf Q3 Financials Report 24% Increase In Net Loss